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Abstract
Chemotherapy is a critical component of malaria control. However, the most deadly malaria pathogen, Plasmodium
falciparum, has repeatedly mounted resistance against a series of antimalarial drugs used in the last decades. Southeast Asia
is an epicenter of emerging antimalarial drug resistance, including recent resistance to the artemisinins, the core
component of all recommended antimalarial combination therapies. Alterations in the parasitic membrane proteins Pgh-1,
PfCRT and PfMRP1 are believed to be major contributors to resistance through decreasing intracellular drug accumulation.
The pfcrt, pfmdr1 and pfmrp1 genes were sequenced from a set of P. falciparum field isolates from the Thai-Myanmar border.
In vitro drug susceptibility to artemisinin, dihydroartemisinin, mefloquine and lumefantrine were assessed. Positive
correlations were seen between the in vitro susceptibility responses to artemisinin and dihydroartemisinin and the
responses to the arylamino-alcohol quinolines lumefantrine and mefloquine. The previously unstudied pfmdr1 F1226Y and
pfmrp1 F1390I SNPs were associated significantly with artemisinin, mefloquine and lumefantrine in vitro susceptibility. A
variation in pfmdr1 gene copy number was also associated with parasite drug susceptibility of artemisinin, mefloquine and
lumefantrine. Our work unveils new candidate markers of P. falciparum multidrug resistance in vitro, while contributing to
the understanding of subjacent genetic complexity, essential for future evidence-based drug policy decisions.
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Introduction
In the 21st century, malaria is still regarded as a major global
infectious disease, with a high pediatric mortality toll in the
Developing World. Chemotherapy is a central tool for manage-
ment of the disease. Unfortunately, the Plasmodium falciparum
parasite, the most deadly human malaria pathogen, has shown an
extraordinary ability to develop resistance to all antimalarials
employed. From the first reports involving quinine [1], to the
ultimate demise of chloroquine in the late 20th century, drug
resistance has been a central factor in the expansion of the disease,
associated with massive mortality and morbidity [2]. Now, in the
21st century, the introduction of new treatment strategies centered
on the combinatorial use of short lived artemisinin derivatives with
long half-life drugs (artemisinin combination therapy, ACT) has
been able to halt resistance and disease spread for the first time in
decades. After its spectacular decrease in incidence following ACT
introduction in some regions [3], this has encouraged optimism for
the prospects of eliminating malaria entirely [4]. Unfortunately, P.
falciparum is again demonstrating its remarkable capacity to evolve
mechanisms of avoiding drug action. Among the presently
employed ACT drugs, decreased sensitivity has been reported to
all the quinoline partner drugs in use, including amodiaquine
[5–7], lumefantrine [8,9] and mefloquine [10]. More recently,
P.falciparum isolates in Cambodia were shown to have developed
tolerance to artemisinin, the core component of the combinations
[11,12]. This tolerance is characterized by prolonged parasite
clearance after treatment [12].
For most ACT partner drugs, the mechanisms behind
antimalarial drug resistant phenotypes are known to be dependent
on alterations in the food vacuole localized proteins Pgh-1 (pfmdr1)
and PfCRT (pfcrt). Both PfCRT and Pgh-1 are drug transporters
believed to contribute to P. falciparum drug resistance through the
decrease of antimalarial accumulation in the target cellular
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e20212
compartment. PfCRT transports drugs from the food vacuole
lumen to the cytoplasm [13,14], an action particularly important
to the development of resistance, considering that several
antimalarials, such the 4-aminoquinolines amodiaquine, desethy-
lamodiaquine and chloroquine, act in this organelle. In contrast,
Pgh-1 has been proposed to actively pump drugs from the
cytoplasm towards the food vacuole [15], which is protective
against antimalarials operating on cytoplasmic targets. Such agents
putatively include the aminoalcohol-quinolines (AAQs) [10], and
possibly artemisinin and its derivatives [16].
There is an emerging idea that these resistance phenomena
actually involve genetic contributions beyond the genes already
mentioned [17,18]. Accordingly, it is likely that another player
could be added to the two transmembrane proteins discussed
earlier: the parasite multidrug resistance protein homologue,
PfMRP1 [19–21]. This class of ABC transporter is involved in
drug evasion in a large range of organisms, and likely plays a
similar function in P. falciparum. In support of this, pfmrp1 has been
proposed to participate in in vivo and/or in vitro parasite response to
chloroquine [18,22], quinine [18,23], lumefantrine [17] and
artemisinin [22].
A full account of the simultaneous participation of each of these
genes in parasite drug susceptibility to multiple drugs has not yet
been performed in detail, in part due to the diversity of their full
open reading frame (ORF). In this report, we have characterized the
phenotype and genotype of a set of P. falciparum adapted parasites
from the area of Mae Sot, Western Thailand-a known epicenter for
multidrug resistance. The work has unveiled different genetic
backgrounds containing a combination of different polymorphisms
associated with resistance to antimalarial drugs used in ACT.
Results
In vitro antimalarial drug susceptibility
50% and 90% inhibitory concentration (IC50 and IC90) values
were measured for artemisinin (ART), dihydroartemisinin (DHA),
mefloquine (MQ) and lumefantrine (LUM) in 46 parasite field
isolates originating from the Thai-Myanmar border. A relatively
large range in IC values was observed for most of the antimalarials
tested, including the artemisinin-type drugs. For these, the median
IC50 values (Max-Min) were 7.4 nM (1.2–19.5 nM) for ART and
1.2 nM (0.3–5.3 nM) for DHA. For the arylaminoalcohols, IC50
values were: MQ and LUM, 92.5 nM (16.5–270.8 nM) and
11.9 nM (2.0–40.8 nM), respectively (Figure 1 and isolates
individual data in Table S1).
There is a significant correlation between the parasitic response
to structurally associated drugs such as sesquiterpene lactone
(ART and DHA) and aminoalcohol quinolines (MQ and LUM)
(Table 1). Interestingly, even though not structurally similar, the
amino alcohol quinolines group and the artemisinin-type com-
pounds form a cluster of cross response (P,0.001).
Polymorphisms detected in pfmdr1, pfmrp1 and pfcrt
Sequence analysis of the full pfmdr1 open reading frame (ORF)
within the isolates revealed 7 SNPs, including two well studied
polymorphic amino acid positions (Y184F and N1042D), as well as
4 other non-synonymous at positions E130K, A750T, S784L,
F1226Y, recently described in parasites from Western Cambodia
[24], and one synonymous at genomic position a747g (Table 2).
Three variants were found within the triplet nucleotide AAT
microsatellite hinge located near the central region of the gene
(Table 2) where 31/46 of the isolates carry an insertion of one
more AAT relative to 3D7 clone reference. Sequencing chro-
matograms of this gene revealed one isolate with mixed infection
present at amino acid position 130, 249 and 750.
All Thai isolates carry an asparagine residue at position 86 and
the SNP with the highest frequency detected was the F1226Y with
23/46 (50%) isolates being 1226Y. The remaining SNPs were
found with low frequency (Table 2). Twenty six of the 46 isolates
analyzed carried increased pfmdr1 copy number, as detected by
realtime PCR. Specifically, 18 carried two copies, while 8 carried
more than three copies (Table S1).
Analysis of the sequencing chromatograms of the pfmrp1 gene
revealed one isolate with mixed infection present at a.a. position
Figure 1. In vitro antimalarials 50% inhibition concentration variance within the isolates. Data are represented in boxplot. The lower and
upper quartiles of the box are 25th and 75th percentile, respectively and the band near the middle of the box is the median. End of the whiskers
represent the 10th and 90th percentile. Dots represent outliers.
doi:10.1371/journal.pone.0020212.g001
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325, 572, 785, 876 and 1007. This isolate does not correspond to
the same mixed isolate detected with pfmdr1 gene sequencing. In
total 11 SNPs (of which 2 synonymous) were identified in the
pfmrp1 ORF. All of these SNPs were published following our
previous global survey of the biodiversity of this gene [17]. SNPs at
positions 191, 325, 437, 572, 785, 876, 1007, 1390 were found in
the isolates with elevated occurrence (Table 2). Increased pfmrp1
gene copy number was not detected.
The pfcrt full open reading frame of each isolate sequenced from
cDNA revealed that all isolates (46/46) carried the pfcrt Dd2-like
open reading frame (ORF) haplotype (C72 /74I/75E/76T/220S/
271E/326S/356T/371I) (Table 2).
After the in vitro analysis in the laboratory for drug susceptibility,
the DNA was extracted from all isolates again to check for
variance and/or selection. The recheck was solely performed in
the polymorphisms with significant association with the in vitro
phenotype. These were the pfmdr1 CNV, as well as the pfmdr1
F1226Y and pfmrp1 F1390I SNPs. Comparison of the DNA
extracted before and after the parasites in vitro adaptation and
expansion, revealed that two isolates lost copies in pfmdr1 gene
during the procedure, changing from 2 to 1 copy (Table S1). Out
of the 46 isolates analyzed, 24 carried increased pfmdr1 copy
number, specifically, 16 carried two copies, while 8 carried more
than three copies. Pyrosequencing of position F1226Y in pfmdr1
and F1390I in pfmrp1 performed in the DNA extracted after the
drug susceptibility tests, revealed isolates with mixed infections
(both alleles) at these polymorphic regions. Table S1 specifies the
characteristics of each isolate including the individual genotype
before and after the drug susceptibility tests performed.
Table 2 shows the genotype frequency of these three most
relevant polymorphisms, from the re-extracted DNA, as this would
reflect the genotype at that point in time. Table 1 also shows
statistical values using data from the re-extracted DNA analysis for
these three polymorphisms as this will reflect a more valid
Table 2. Single Nucleotide Polymorphisms in the studied transporter genes.
Nucleotide position Triplet nucleotide change Amino acid position Amino acid change
Frequency
(proportion)
pfmdr1
388 GAA-AAA 130 E-K 0.13 (6/46)+1mix
551 TAT-TTT 184 Y-F 0.09 (4/46)
747 GGA-GGG 249 syn 0.13 (6/46)+1mix
1972–1980 del 3xAAT 658 _ _ _ 0.09 (4/46)
1978–1980 del AAT 660 _ 0.24 (11/46)
1980 ins AAT 660+1 +N 0.67 (31/46)
2248 GCA-ACA 750 A-T 0.15 (7/46)+1mix
2351 TCA-TTA 784 S-L 0.02 (1/46)
3124 AAT-GAT 1042 N-D 0.02 (1/46)
3677 TTT-TAT 1226 F-Y 0.50 (23/46)+1mix
pfmrp1
300 GCA-GCT 100 syn 0.04 (2/46)
571 CAT-TAT 191 H-Y 0.96 (44/46)
974 AAT-AGT 325 N-S 0.20 (9/46)+1mix
1309 TCA-GCA 437 S-A 0.96 (44/46)
1716 TTC-TTG 572 F-L 0.39 (18/46)+1mix
2353 CAT-AAT 785 H-N 0.50 (23/46)+1mix
2626 ATA-GTA 876 I-V 0.74 (34/46)+1mix
3020 ACG-ATG 1007 T-M 0.50 (23/46)+1mix
3603 GAA-GAG 1201 syn 0.04 (2/46)
4168 TTT-ATT 1390 F-I 0.17 (8/46)+2mix
4451 GAA-GGA 1484 E-G 0.02 (1/46)
pfcrt
222 ATG-ATT 74 M-I 1 (46/46)
223 AAT-GAT 75 N-D 1 (46/46)
225 AAT-GAA 75 N-E 1 (46/46)
227 AAA-ACA 76 K-T 1 (46/46)
658 GCC-TCC 220 A-S 1 (46/46)
811 CAA-GAA 271 Q-E 1 (46/46)
977 AAC-AGC 326 N-S 1 (46/46)
1067 ATA-ACA 356 I-T 1 (46/46)
1112 AGA-ATA 371 R-I 1 (46/46)
doi:10.1371/journal.pone.0020212.t002
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association with the in vitro drug susceptibility tests performed. To
note that this genotype variance before and after adaptation, did
not change the determined statistically significant genotype-
phenotype association.
In vitro phenotype-genotype associations
Since all isolates had the same haplotype for the pfcrt gene, a
possible association could not be assessed between the pfcrt SNPs
and IC’s values. As previously observed [8,10,16,25], and herein
confirmed, an increased gene copy number of pfmdr1 was clearly
associated with higher IC50’s for MQ, LUM and ART (P,0.0042)
(Table 1, Figure 2). From the seven SNPs found in pfmdr1, only
one, F1226Y, was found to be associated with decreased sensitivity
to ART, MQ and LUM IC50 and IC90 (Table 1, Figure 3). The
average IC50 (6SE) of the pfmdr1 1226Y allele was 10.09(61.12),
135.18(614.57), and 17.77(61.95) nM, values significantly higher
compared with the non-carriers: 5.43(60.98), 73.06(614.08) and
9.47(61.90) nM, for each drug, respectively. Among the 11 SNPs
found in pfmrp1 (Table 2), F1390I was documented to significantly
modulate the in vitro drug response phenotypes (Table 1). Carriers
of the F1390 allele were less susceptible to ART, MQ and LUM,
with average IC50’s of 8.96(60.92), 121.71(612.17) and
15.56(61.71) nM, compared to 1390I carriers with values of
3.30(60.86), 37.25 (69.31) and 6.08(61.87) nM, respectively
(Figure 4). Interestingly, even though pfmdr1 F1226Y and pfmrp1
F1390I alleles have very similar association profiles, both seem to
represent independent actions, as they were not found together in
the same Thai isolate in more instances than would randomly be
expected (P.0.05).
We have further analyzed the effects of the available
combinations (haplotypes) of the most relevant polymorphisms,
i.e. the pfmrp1 F1390I and pfmdr1 F1226Y SNPs, as well as pfmdr1
gene copy number variation (CNV). In particular, a trend for an
identical progressive increase in IC50 was evident for the
antimalarials ART, MQ and LUM (Figure 5), associated with
the following sequence of haplotypes (from more sensitive to more
resistant associated):
i) IF1: pfmrp1 1390I+pfmdr1 F1226+pfmdr1 CNV,1.5;
ii) FF1: pfmrp1 F1390+pfmdr1 F1226+pfmdr1 CNV,1.5;
iii) FY1: pfmrp1 F1390+pfmdr1 1226Y+pfmdr1 CNV,1.5;
iv) FF2: pfmrp1 F1390+pfmdr1 F1226+pfmdr1 CNV.1.5;
v) FY2: pfmrp1 F1390+pfmdr1 1226Y+pfmdr1 CNV.1.5.
Crystal structures of ABC transporters from P. falciparum are still
not available. In lieu of this, an approach based on computational
molecular modeling with known reference structures was applied
to explore putative functional implications of relevant polymor-
phisms.
As we previously reported [17], PfMRP1 contains 12 trans-
membranes domains (TMs) and 2 NBDs, presenting a full ABC
transporter structure (i.e. 6+6 TMs), similar to Pgh-1 [26]. Residue
1390 is expected to be localized in transmembrane 11 (Figure 6A).
Based on the Msba ABC transporter crystal 3B60 and using
HHpred, a homology detection and structure prediction server, we
were able to develop a model for the second transmembrane
spanning domain 2 (Figure 6B).
The residues 1034 and 1042 of Pgh-1 are located in TM11, an
important domain for antimalarial resistance [27]. This is likely due
to alterations in a drug pocket region of the transporter. Similarly,
the involvement of polymorphisms related to antimalarial resis-
tance in TM11 of PfMRP1 suggests the existence of a drug-binding
pocket in this region. Amino acid residue 1226 in Pgh-1 is localized
in a non-conserved insertion in the reference structure, not allowing
the possibility to perform homology modeling.
Discussion
The global implementation of ACT has led to a significant
world-wide reduction in malaria incidence. This, in turn, has
Figure 2. Significant association of pfmdr1 copy number variation and in vitro IC50’s for ART, MQ and LUM. Significant relationship
between average in vitro drugs tested IC50’s and pfmdr1 CNV polymorphism. Data described in Table S2. ,1.5: 1 gene copy of pfmdr1 (#22 isolates).
.1.5: 2 and 3 gene copies of pfmdr1 (#24 isolates). T-test statistics was applied. P value ,0.0042 is consider significant after Bonferroni correction.
Error bars represent SE.
doi:10.1371/journal.pone.0020212.g002
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motivated policymakers and donors to adopt a more optimistic
view of the prospect of eliminating malaria completely in vast
tropical endemic regions [4]. In order to make this a reality, and
considering the epidemiological consequences of chloroquine
resistance [2], we must understand the mechanisms behind
incidences of parasite resistance to ACT. This is particularly
urgent, as there is accumulating evidence of development of
resistance in the field - or at least significant decreases in parasite
response against artemisinin derivatives [11,12] and to the long
half-life ACT partner drugs [6,9,10,16,28,29].
Through the search for drug resistance molecular markers, as
expressed by their modulation of the specific parasite antimalarial
Figure 4. Significant association of pfmrp1 F1390I and IC50’s for ART, MQ and LUM. Significant relationship between average in vitro drugs
tested IC50’s and pfmrp1 F1390I polymorphism. Data described in Table S2. Black bars are average IC50 of 36 isolates with F1390 allele. Grey bars are
average IC50 of 8 isolates with 1390I allele. T-test statistics was applied. P value ,0.0042 is consider significant after Bonferroni correction. Error bars
represent SE.
doi:10.1371/journal.pone.0020212.g004
Figure 3. Significant association of pfmdr1 F1226Y and IC50’s for ART, MQ and LUM. Significant relationship between average in vitro
drugs tested IC50’s and pfmdr1 F1226Y polymorphism. Data described in Table S2. Black bars are average IC50 of 22 isolates with F1226 allele. Grey
bars are average IC50 of 23 isolates with 1226Y allele. T-test statistics was applied. P value ,0.0042 is consider significant after Bonferroni correction.
Error bars represent SE.
doi:10.1371/journal.pone.0020212.g003
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in vitro IC’s, our results reinforced the importance of pfmdr1 copy
number as a central factor in the response of P. falciparum to drugs
of different structures. The association between increased copy
number and decreased sensitivity to ART, MQ and LUM
confirms previous associative data in vivo [8,10], as do strictly
controlled gene knock-down experiments in parasite clones [30].
Most relevant, we have identified SNPs that constitute new drug
resistance candidate markers. These are comprised of two recently
described polymorphisms: pfmdr1 F1226Y [24] and pfmrp1 F1390I
[17]. Structural analysis performed for polymorphism F1390I in
PfMRP1 showed it to be localized within transmembrane 11,
which has been proposed to be part of a substrate pocket in several
ABC transporters, including Pgh-1. The similar localization and
involvement of this polymorphism for antimalarial resistance
suggests it has an analogous roll to the S1034C and N1042D SNPs
observed in Pgh-1 [27,31]. Importantly, directed mutagenesis
studies performed in the human and murine PfMRP1 have
pointed to TM16, putatively equivalent to the PfMRP1 TM11 in
functional terms, as a central component that defines transport
specificity [32–36]. In this context, it is conceivable that the TM11
Figure 6. 2D structure of PfMRP1 and F1390I SNP location. A: Secondary structure analysis of transmembrane spanning domain 2 (TSD2) of
PfMRP1 and F1390I SNP localization. B: Computational homology modelling was performed at HHpred. Alignment for best template was performed
using Psi-blast and with local alignment. The template from the best E-score alignment was based in the Msba ABC transporter crystal 3B60 then
used in Modeller software to generate a model. Models were visualized with Yasara software.
doi:10.1371/journal.pone.0020212.g006
Figure 5. Haplotype and in vitro IC50’s association. Relationship between average in vitro drug tested IC50’s and pfmrp1 F1390I, pfmdr1 F1226Y
and pfmdr1 CNV polymorphisms. Bars represent different haplotypes. IF1 (#6 isolates): pfmrp1 1390I, pfmdr1 F1226 and 1 gene copy of pfmdr1. FF1
(#9 isolates): pfmrp1 F1390, pfmdr1 F1226 and 1 gene copy of pfmdr1. FY1 (#5 isolates): pfmrp1 F1390, pfmdr1 1226Y and 1 gene copy of pfmdr1. FF2
(#6 isolates): pfmrp1 F1390, pfmdr1 F1226 and .1 gene copy of pfmdr1. FY2 (#15 isolates): pfmrp1 F1390, pfmdr1 1226Y and .1 gene copy of
pfmdr1. T-test statistics was applied to see significant difference between haplotypes. *: P,0.05. Error bars represent SE.
doi:10.1371/journal.pone.0020212.g005
P. falciparum Transporter Genes and Drug Resistance
PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e20212
located F1390I SNP is changing the specificity of the interactions
between the PfMRP1 and the antimalarials ART, MQ and LUM .
The pfmdr1 F1226Y and pfmrp1 F1390I SNPs seem to have an
inter-independent, but very similar quantitative effect on the
simultaneous response in vitro drug susceptibility of the parasite
against the ART/MQ/LUM, which to a certain extent parallels
what is observed with the pfmdr1 increased copy number. In
particular, successive accumulation of these SNPs, combined with
the presence of pfmdr1 CNV polymorphism, seem to have a
cumulative contribution (Figure 5). As for the pfmdr1 F1226Y SNP,
it is conceivable that, as previously proposed for the pfmdr1 86N
allele [37], its presence might enhance the contribution of the
increased copy number of this gene. The preferential presence of
F1226Y among the analyzed isolates with pfmdr1 copy number
amplifications might hence be the result of a drug driven selection,
reinforcing the notion that the phenotypical consequences of the
pfmdr1 CNV polymorphism is modulated by the nature of the
ORF sequence involved.
In this work we unveil a potential new candidate pathway
towards resistance, particularly important for two of the most
important ACTs used worldwide: artemether-LUM (CoartemH,
Novartis, Basel) and artesunate-MQ (Artequin PaediatricH,
Mepha Ltd, Aesch, Switzerland). It would be of interest to
retrospectively explore in vivo trials with these combinations in
search of confirmatory selection events for these mutations, in
particular the case of artesunate-MQ, the definition of two
categories of pfmdr1 CNV. For the F1226Y SNP, its association
with clinical failure might be of relevance. Interpreting the pfmrp1
F1390I/ pfmdr1 F1226Y/ pfmdr1 CNV haplotype analysis, two
observations deserve mention as is evident from figure 5. The
introduction of the pfmdr1 CNV is associated with an abrupt leap
in MQ IC50 values, confirming the well established status of this
type of mutation as a valuable specific marker for P. falciparum
resistance against MQ [10,16,38]. The pfmdr1 CNV alone seems to
have a less dramatic but significant effect against ART and LUM,
again confirming previous findings [8,10,27]. Fortunately, ART is
not commonly used in ACT; the partners of LUM and MQ being
artemether and artesunate, respectively.
Although previous reports have shown association of pfmdr1
CNV with artesunate and DHA [8,10], this study did not find any
significant association of DHA with pfmdr1 CNV neither with
pfmrp1 F1390I or pfmdr1 F1226Y. Nevertheless, it showed
significant positive correlation with ART, MQ and LUM in vitro
susceptibility responses (Table 1).
Taken together, these data point towards the necessity for
further research defining molecular markers for the development
of resistance against the artemisinin derivative+amino-alcohol
quinoline partner drugs, as these two structurally different classes
of antimalarials seem to share, at least to some extent, mechanisms
of drug action evasion. The pfmrp1 F1390I and pfmdr1 F1226Y
SNPs, in conjugation with the well established pfmdr1 CNV,
represent likely candidates. The selection of these SNPs might be a
pivotal step towards understanding CoartemH resistance in
locations where this ACT is a first line strategy, namely in a
significant number of African countries, where pfmdr1 CNV are
presently rare, but nevertheless existent [39–41].
The precise mechanistic contribution of each one of these
mutations remains an open question. From our results and others,
a simple model compiling the available data can be proposed
(figure 7), partly extending from previous suggestions [17,22,29].
The central assumption is that ART, LUM and MQ drugs have
their main pharmacological targets located in the cytoplasmic
compartment [29] while PfMRP1, located in the plasma
membrane, pumps them out of the cell, thereby reducing the
intra-cytoplasmatic concentrations of the drugs. Pgh-1, inserted in
the food vacuole membrane, would contribute to further drug
expulsion from the cytoplasm by transporting these drugs towards
the lumen of this organelle.
From our research, we are aware that the pfmrp1 F1390I SNP is
present in the African continent [17]. This is at least the case on
the West coast where, incidentally, MQ has been traditionally
considered to have lower efficacy compared with the Eastern
regions of the continent. No information exists out of SE Asia
concerning the pfmdr1 F1226Y SNP, highlighting the need for
more comprehensive studies on this SNP, particularly in Africa,
where CoartemH is the most common first line malaria treatment.
In conclusion, we propose novel potential markers of in vitro
multidrug resistance against ACT drugs, particularly involving the
pivotal artesunate-MQ and artemether-LUM combinations.
These results further reinforce the complexity of emerging
resistance to ACTs, consisting of several different molecular
contributions, and hence multiple genetic markers.
Materials and Methods
Ethics statement
Collection protocols were approved by the Ethical Committee
of the Faculty of Tropical Medicine, Mahidol University, Bangkok
Figure 7. Proposed model for mode of action of the polymorphisms found. The central assumption is that ART, LUM and MQ drugs have
their main pharmacological targets located in the cytoplasmic compartment while PfMRP1, operates by reducing the intra-cytoplasmatic
concentrations by effluxing them out of the cell. Pgh-1, on its turn will contribute to further drug expulsion from the cytoplasm by transporting these
drugs towards the lumen of the food vacuole.
doi:10.1371/journal.pone.0020212.g007
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and Oxford Tropical Research Ethics Committee (OXTREC) at
University of Oxford, UK.
The attending physician assured provision of written informed
consent in the local language. After having obtained the patients
or parents informed consent, venous blood was collected.
Parasites
Isolates of P. falciparum were collected from malaria patients
before treatment between the year 2002 and 2008 in Mae Sot,
Thailand. Forty six isolates were chosen to be enrolled in this study.
Parasites were cryo-preserved in liquid nitrogen until further use.
Culture adaptation of the isolates was performed in 5% human
O+ RBCs in RPMI 1640 culture medium supplemented with 10%
L-glutamine, 0.05% gentamicine (GibcoH/InvitrogenTM, Carls-
bad, CA, USA) and 10% human AB+ serum. The cultures were
incubated at 37uC with addition of a gas mixture (5% O2, 5%
CO2 in N2) and shook at 50 rpm.
In vitro drug susceptibility assays
Chemosensitivity testing in vitro was performed with 4
antimalarial drugs. Artemisinin-282.33 MW, dihydroartemisinin-
284.35 MW and mefloquine hydrochloride-414.77 MW, were
purchased from Sigma-Aldrich (St louis, MO, USA) and
lumefantrine-530 MW (LUM) from Novartis (Basel, Switzerland).
The drugs were reconstituted in different solvents depending on
their solubility. The IC’s values were assessed using a Histidine-
Rich Protein 2 based Double-Site Sandwich Enzyme-Linked
Immunosorbent Assay [42]. Briefly, the parasite isolates were
cultured (synchronized at ring stage containing 0,05% parasitae-
mia and 1,5% hematocrite) in the presence of serial dilutions of
antimalarial drugs (ART, DHA, LUM and MQ). After 72 hours
of culturing at 37uC in candle jars, cells were then lysed by freeze-
thawing for ELISA analysis. Four independent assays were
performed for each field isolate and 3D7 reference strain IC50
measured once a month for drug quality control. 3D7 strain was
obtained from Prof. D. Walliker (Department of Animal and
population genetics, University of Edinburgh, UK).
Nucleic acids extraction
Blood samples from each culture-adapted isolate were centri-
fuged and 50 mL packed parasitized RBC frozen for DNA
extraction. For RNA extraction 150 mL of PBS plus 300 mL of
Lysis buffer (Applied BiosystemsTM, Fresno, CA, USA) were
added to 50 mL packed parasitized RBC. The mix was kept at
220uC until RNA extraction. DNA and RNA extraction was
carried out using an ABIPRISMH6100 Nucleic Acid PrepStationH
(Applied BiosystemsTM, Fresno, CA, USA) according to the
recommendations of the manufacturer. cDNA synthesis was
carried out using a High-Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, Fresno, CA, USA).
Drug transporter genes open reading frame sequencing
All 46 isolates were fully sequenced for pfmdr1 and pfmrp1 genes
from gDNA and the pfcrt gene was sequenced from cDNA. Amplifi-
cation and sequencing primers for the pfmrp1 were as described [17]
and for pfmdr1 and pfcrt genes the primers are shown in supplementary
supporting information (Material and Methods S1). Amplicon
fragments were sequenced by Macrogen Inc. (Seoul, Korea).
The SequencherTM software versions 4.6 (Gene Codes
Corporation, Ann Arbor, MI) was used to analyze the sequence
output with the 3D7 sequence reference of PFE1150w (pfmdr1),
PFA0590w (pfmrp1) and MAL7P1.27 (pfcrt) downloaded from
Plasmo DataBase (http://plasmodb.org/).
Gene copy number amplification of pfmdr1 and pfmrp1
Relative quantification of pfmdr1 and pfmrp1 genes in all isolates
was performed using housekeeping gene tubulin beta chain
putative (PF10_0084). TaqManH probes and primers for pfmdr1
were as described [10]. For pfmrp1, new primers (fw 59-AGT AGA
AGG AAG AGA CAT TCG AAC ATA-39 and rev 59-CAA AAG
AAG ATT GAG CTA AAA TAC CAA-39) and probe (6-FAM,
MGBNFQ 59-AAT AGA AAA GGA GAA GAT AG-39) were
designed (Applied BiosystemsTM, Fresno, CA, USA) to be
performed as a multiplex using the same housekeeping gene
primers and probe employed in pfmdr1 analysis.
P.falciparum DNA from 3D7, K1 and FCB reference strains were
used as calibrators and positive controls (known copy number
variation for pfmdr1 gene). Multiplex amplification reactions were
done in triplicate in 96 well plates with 20 ml containing TaqManH
Gene Expression Mastermix (Applied Biosystems), 300 nM of
each forward and reverse primer, 100 nM of TaqManH probe
from both target and housekeeping gene and 4 mL of gDNA. The
thermal cycle profile was 50uC 2 min, 95uC 10 min and forty-five
cycles of 95uC 15 s and 60uC 1 min. PCR was performed in ABI
PRISMH 7000 Sequence Detection System (Applied Biosys-
temsTM, Fresno, CA, USA). The detection threshold was set
above the mean baseline value for the first 6–15 cycles.
Genotype re-analysis after culture adaptation
To check the existence of any variance or selection of parasites
genotypes in the field isolates after in vitro adaptation, the DNA was
extracted from the culture plates (row ‘‘A’’/no drug control) in
which the last tests for ICs was performed.
Genotyping was done only in the polymorphisms herein
observed to be significantly associated with in vitro susceptibility:
the pfmdr1 CNV, pfmdr1 F1226Y and pfmrp1 F1390I. The method
to recheck pfmdr1 CNV was the same as described above. For
pfmdr1 F1226Y and pfmrp1 F1390I pyrosequencing was the
preferred method due to time/cost efficiency. The pyrosequencing
protocol and primers were designed with Pyrosequencing assay
design software, version 1.0 (Biotage AB, Uppsala, Sweden).
Amplification conditions, pyrosequencing primers and the nucle-
otide dispensation orders are described in supplementary support-
ing information (Material and Methods S1).
Computational molecular analysis
Secondary structure analysis of transmembrane spanning
domain 2 (TSD2) of PfMRP1 was performed with SOSUI server
[43]. Computational homology modeling was performed at
HHpred-Homology detection & structure prediction by HMM-
HMM comparison server (http://toolkit.tuebingen.mpg.de/
hhpred). Alignment for best template was performed using Psi-
blast with 8 interactions and with local alignment. The template
from the best E-score alignment for the second transmembrane
spanning domain 2 based in the Msba ABC transporter crystal
3B60, was then used in Modeller software to generate a model.
Models were visualized with Yasara software [44].
Statistical analysis
50% and 90% inhibitory concentrations were calculated by
nonlinear regression analysis (http://malaria.farch.net). Statistical
analysis was carried out using SigmaPlot for windows version 11.0.
Pearson Correlation was used to assess linear relations. In vitro drug
susceptibility phenotype and genotype association (Table 1 and
Table S2) was performed with T-test with equal variances assumed
(2-tailed). For comparison, Bonferroni-adjusted level of signifi-
cance would be: P value ,0.0042. Isolates that harbors both
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alleles (mixed infection) in the determined polymorphic region
were excluded from the statistical analysis.
Supporting Information
Table S1 Comprehensive data of each isolate genotype
and in vitro drug susceptibility values.
(XLS)
Table S2 Relationship between average in vitro drugs
tested IC’s and relevant polymorphisms.
(XLS)
Material and Methods S1 PCR program, mastermix and
primer sequences for pfmdr1 and pfcrt ORF sequencing and pfmdr1
F1226Y and pfmrp1 F1390I genotyping by pyrosequencing.
(DOC)
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